A Novel <i>CLTC::RPS6KB1</i> Fusion in a Poorly Differentiated Carcinoma Involving the Lung and Mediastinum

Cancer genetics studies have dramatically advanced the understanding of the molecular drivers in various types of neoplasms. This progress is also leading to the discovery of more new molecular agents to block those drivers, which has significantly improved cancer patient survival, especially in non-small cell lung cancer (NSCLC). However, in about 25% of NSCLC tumors molecular drivers are not yet known. Herein, we present a poorly differentiated carcinoma involving lung and mediastinum. Next generation sequencing-based RNAseq identified a novel fusion, <i>CLTC::RPS6KB1</i>, while no other known drivers were present.